Reata and Invitae are sponsoring KIDNEYCODE, a no-charge genetic testing program, to help nephrologists identify patients with genetic forms of CKD.
- Seventy-eight percent of patients with eGFR below normal, a family history of CKD, and hematuria have been found to have Alport syndrome in the KidneyCode program including variants of uncertain significance in COL4A3, COL4A4, and COL4A5 genes.
- Of the tests that have results that we can access, approximately half have been positive for Alport syndrome, and half of these patients were previously misdiagnosed with other forms of CKD including variants of uncertain significance in COL4A3, COL4A4, and COL4A5 genes.
Disclaimer
Bardoxolone methyl and omaveloxolone are investigational drugs. Safety and efficacy have not been established by any agency.